Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
uniQure selloff on clinical hold brings good entry point, says Chardan » 10:29
12/22/20
12/22
10:29
12/22/20
10:29
QURE

uniQure

$40.25 /

+1.75 (+4.55%)

The 16% selloff yesterday…

The 16% selloff yesterday in uniQure shares after the FDA placed a clinical hold on its Phase III trial of AAV5-based gene therapy EtranaDez in hemophilia B creates a good entry point, Chardan analyst Gbola Amusa tells investors in a research note. The clinical hold relates to a "possibly related" serious adverse event associated with a preliminary diagnosis of hepatocellular carcinoma in one patient treated with EtranaDez in October 2019, the analyst points out. Amusa adds that uniQure's deal with CSL Behring has no opt-out based on the clinical hold, the patient was "extremely high risk," and that the company's guidance for a Biologics License Application filing is unchanged for the second half of 2021. Amusa keeps a Buy rating on uniQure with an $85 price target.

ShowHide Related Items >><<
QURE uniQure
$40.25 /

+1.75 (+4.55%)

QURE uniQure
$40.25 /

+1.75 (+4.55%)

12/22/20 Jefferies
uniQure's EtranaDez unlikely to raise HCC risk in hemB patients, says Jefferies
12/22/20 RBC Capital
uniQure price target lowered to $53 from $61 at RBC Capital
12/22/20 H.C. Wainwright
uniQure price target lowered to $80 from $85 at H.C. Wainwright
12/21/20 Stifel
AMT-061 clinical hold 'obviously negative,' implications less clear, says Stifel
QURE uniQure
$40.25 /

+1.75 (+4.55%)

QURE uniQure
$40.25 /

+1.75 (+4.55%)

QURE uniQure
$40.25 /

+1.75 (+4.55%)

Recommendations
uniQure's EtranaDez unlikely to raise HCC risk in hemB patients, says Jefferies » 07:42
12/22/20
12/22
07:42
12/22/20
07:42
QURE

uniQure

$38.51 /

-7.39 (-16.10%)

After uniQure announced…

After uniQure announced its Phase 3 HOPE-B trial for EtranaDez was placed on clinical hold by the FDA after a safety report of a preliminary diagnosis of hepatocellular carcinoma, or HCC, in one patient, Jefferies analyst Suji Jeong noted that no other cases of liver cancer have been reported in uniQure's clinical and animal studies, or in other AAV gene therapy trials. Given those facts, and the fact that the patient already carried multiple risk factors for liver cancer, Jeong views it as unlikely that EtranaDez increases HCC risk in hemophilia B population, the analyst tells investors. Joeng maintains a Buy rating on uniQure with a $62 price target.

ShowHide Related Items >><<
QURE uniQure
$38.51 /

-7.39 (-16.10%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

12/22/20 RBC Capital
uniQure price target lowered to $53 from $61 at RBC Capital
12/22/20 H.C. Wainwright
uniQure price target lowered to $80 from $85 at H.C. Wainwright
12/21/20 Stifel
AMT-061 clinical hold 'obviously negative,' implications less clear, says Stifel
12/21/20 H.C. Wainwright
uniQure price target raised to $85 from $80 at H.C. Wainwright
QURE uniQure
$38.51 /

-7.39 (-16.10%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

Recommendations
uniQure price target lowered to $53 from $61 at RBC Capital » 06:28
12/22/20
12/22
06:28
12/22/20
06:28
QURE

uniQure

$38.51 /

-7.39 (-16.10%)

RBC Capital analyst Luca…

RBC Capital analyst Luca Issi lowered the firm's price target on uniQure to $53 from $61 and keeps an Outperform rating on the shares after EtranaDez was put on clinical hold due to a single case of suspected hepatocellular carcinoma. Issi believes this tilts the risk/benefit profile less favorably and increases regulatory risk, though thinks the CSL deal is unlikely at risk. The analyst is bullish on the Huntington's program going into 2021.

ShowHide Related Items >><<
QURE uniQure
$38.51 /

-7.39 (-16.10%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

12/22/20 H.C. Wainwright
uniQure price target lowered to $80 from $85 at H.C. Wainwright
12/21/20 Stifel
AMT-061 clinical hold 'obviously negative,' implications less clear, says Stifel
12/21/20 H.C. Wainwright
uniQure price target raised to $85 from $80 at H.C. Wainwright
12/09/20 Jefferies
uniQure price target raised to $62 from $55 at Jefferies
QURE uniQure
$38.51 /

-7.39 (-16.10%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

Recommendations
uniQure price target lowered to $80 from $85 at H.C. Wainwright » 06:13
12/22/20
12/22
06:13
12/22/20
06:13
QURE

uniQure

$38.51 /

-7.39 (-16.10%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Patrick Trucchio lowered the firm's price target on uniQure to $80 from $85 and reiterates a Buy rating on the shares after the company announced that its hemophilia B program has been placed on clinical hold by the FDA. The analyst notes that patient dosing in each of uniQure's three hemophilia B gene therapy trials is complete so the existing timelines for HOPE-B top-line data in the second half of 2021 and a potential Biologics License Application submission remain intact.

ShowHide Related Items >><<
QURE uniQure
$38.51 /

-7.39 (-16.10%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

12/21/20 Stifel
AMT-061 clinical hold 'obviously negative,' implications less clear, says Stifel
12/21/20 H.C. Wainwright
uniQure price target raised to $85 from $80 at H.C. Wainwright
12/09/20 Jefferies
uniQure price target raised to $62 from $55 at Jefferies
12/09/20 Mizuho
uniQure price target raised to $52 from $46 at Mizuho
QURE uniQure
$38.51 /

-7.39 (-16.10%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:39
12/21/20
12/21
16:39
12/21/20
16:39
MRNA

Moderna

$138.24 /

-1.99 (-1.42%)

, PFE

Pfizer

$37.37 /

-0.315 (-0.84%)

, BNTX

BioNTech

$106.36 /

+2.27 (+2.18%)

, LMT

Lockheed Martin

$349.32 /

-6.91 (-1.94%)

, AJRD

Aerojet Rocketdyne

$52.78 /

+10.65 (+25.28%)

, RP

RealPage

$87.27 /

+19.63 (+29.02%)

, NKE

Nike

$143.97 /

+4.93 (+3.55%)

, WBAI

500.com

$3.79 /

+1.135 (+42.75%)

, NK

NantKwest

$16.02 /

+5.78 (+56.45%)

, QURE

uniQure

$38.51 /

-7.39 (-16.10%)

, FGEN

FibroGen

$40.01 /

-3.98 (-9.05%)

The major averages…

ShowHide Related Items >><<
WBAI 500.com
$3.79 /

+1.135 (+42.75%)

RP RealPage
$87.27 /

+19.63 (+29.02%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

PFE Pfizer
$37.37 /

-0.315 (-0.84%)

NKE Nike
$143.97 /

+4.93 (+3.55%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

LMT Lockheed Martin
$349.32 /

-6.91 (-1.94%)

FGEN FibroGen
$40.01 /

-3.98 (-9.05%)

AJRD Aerojet Rocketdyne
$52.78 /

+10.65 (+25.28%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/21/20 SVB Leerink
Moderna price target raised to $69 from $60 at SVB Leerink
12/21/20 Oppenheimer
Moderna price target raised to $178 from $157 at Oppenheimer
12/18/20 Barclays
Moderna price target raised to $169 from $84 at Barclays
PFE Pfizer
$37.37 /

-0.315 (-0.84%)

12/16/20
Fly Intel: Top five analyst downgrades
12/16/20 KeyBanc
Maravai Lifesciences initiated with an Overweight at KeyBanc
12/16/20 RBC Capital
Pfizer downgraded to Sector Perform from Outperform at RBC Capital
BNTX BioNTech
$106.36 /

+2.27 (+2.18%)

12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
12/14/20 Citi
Arcturus Therapeutics price target raised to $133 from $62 at Citi
12/08/20 Goldman Sachs
Goldman says FDA briefing documents supportive of approval for Pfizer vaccine
LMT Lockheed Martin
$349.32 /

-6.91 (-1.94%)

12/22/20 Credit Suisse
Lockheed Martin price target raised to $409 from $400 at Credit Suisse
12/22/20 Truist
Aerojet Rocketdyne downgraded to Hold from Buy at Truist
12/21/20 Canaccord
Boeing not in position to challenge Aerojet bid, says Canaccord
12/21/20 RBC Capital
Aerojet Rocketdyne price target raised to $56 from $51 at RBC Capital
AJRD Aerojet Rocketdyne
$52.78 /

+10.65 (+25.28%)

12/21/20 Truist
Aerojet Rocketdyne downgraded to Hold from Buy at Truist
RP RealPage
$87.27 /

+19.63 (+29.02%)

12/22/20 JMP Securities
RealPage price target raised to $101 from $80 at JMP Securities
12/22/20 Baird
RealPage downgraded to Neutral from Outperform at Baird
12/21/20 BMO Capital
RealPage downgraded to Market Perform from Outperform at BMO Capital
12/21/20 RBC Capital
RealPage downgraded to Sector Perform from Outperform at RBC Capital
NKE Nike
$143.97 /

+4.93 (+3.55%)

12/22/20 Argus
Nike price target raised to $165 from $140 at Argus
12/21/20 Jefferies
Nike price target raised to $140 from $117 at Jefferies
12/21/20 Baird
Nike near-term estimate upside limited, says Baird
12/21/20 Raymond James
Nike price target raised to $155 from $140 at Raymond James
WBAI 500.com
$3.79 /

+1.135 (+42.75%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
QURE uniQure
$38.51 /

-7.39 (-16.10%)

12/22/20 Jefferies
uniQure's EtranaDez unlikely to raise HCC risk in hemB patients, says Jefferies
12/22/20 RBC Capital
uniQure price target lowered to $53 from $61 at RBC Capital
12/22/20 H.C. Wainwright
uniQure price target lowered to $80 from $85 at H.C. Wainwright
12/21/20 Stifel
AMT-061 clinical hold 'obviously negative,' implications less clear, says Stifel
FGEN FibroGen
$40.01 /

-3.98 (-9.05%)

12/21/20 Mizuho
FibroGen should be bought on PDUFA extension weakness, says Mizuho
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
RP RealPage
$87.27 /

+19.63 (+29.02%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

PFE Pfizer
$37.37 /

-0.315 (-0.84%)

NKE Nike
$143.97 /

+4.93 (+3.55%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

LMT Lockheed Martin
$349.32 /

-6.91 (-1.94%)

FGEN FibroGen
$40.01 /

-3.98 (-9.05%)

BNTX BioNTech
$106.36 /

+2.27 (+2.18%)

AJRD Aerojet Rocketdyne
$52.78 /

+10.65 (+25.28%)

  • 23
    Jul
  • 25
    Jun
  • 20
    May
  • 19
    May
  • 12
    Feb
  • 06
    Feb
QURE uniQure
$38.51 /

-7.39 (-16.10%)

PFE Pfizer
$37.37 /

-0.315 (-0.84%)

NKE Nike
$143.97 /

+4.93 (+3.55%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

LMT Lockheed Martin
$349.32 /

-6.91 (-1.94%)

RP RealPage
$87.27 /

+19.63 (+29.02%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

PFE Pfizer
$37.37 /

-0.315 (-0.84%)

NKE Nike
$143.97 /

+4.93 (+3.55%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

LMT Lockheed Martin
$349.32 /

-6.91 (-1.94%)

FGEN FibroGen
$40.01 /

-3.98 (-9.05%)

BNTX BioNTech
$106.36 /

+2.27 (+2.18%)

AJRD Aerojet Rocketdyne
$52.78 /

+10.65 (+25.28%)

PFE Pfizer
$37.37 /

-0.315 (-0.84%)

NKE Nike
$143.97 /

+4.93 (+3.55%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

FGEN FibroGen
$40.01 /

-3.98 (-9.05%)

BNTX BioNTech
$106.36 /

+2.27 (+2.18%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 13:35
12/21/20
12/21
13:35
12/21/20
13:35
LMT

Lockheed Martin

$351.88 /

-4.35 (-1.22%)

, AJRD

Aerojet Rocketdyne

$52.10 /

+9.97 (+23.66%)

, RP

RealPage

$87.43 /

+19.79 (+29.26%)

, NKE

Nike

$144.37 /

+5.33 (+3.83%)

, TSLA

Tesla

$664.48 /

-1.32 (-0.20%)

, WBAI

500.com

$4.17 /

+1.515 (+57.06%)

, NK

NantKwest

$16.78 /

+6.54 (+63.87%)

, QURE

uniQure

$37.97 /

-7.93 (-17.28%)

, FGEN

FibroGen

$38.75 /

-5.24 (-11.91%)

The major averages were…

ShowHide Related Items >><<
WBAI 500.com
$4.17 /

+1.515 (+57.06%)

TSLA Tesla
$664.48 /

-1.32 (-0.20%)

RP RealPage
$87.43 /

+19.79 (+29.26%)

QURE uniQure
$37.97 /

-7.93 (-17.28%)

NKE Nike
$144.37 /

+5.33 (+3.83%)

NK NantKwest
$16.78 /

+6.54 (+63.87%)

LMT Lockheed Martin
$351.88 /

-4.35 (-1.22%)

FGEN FibroGen
$38.75 /

-5.24 (-11.91%)

AJRD Aerojet Rocketdyne
$52.10 /

+9.97 (+23.66%)

LMT Lockheed Martin
$351.88 /

-4.35 (-1.22%)

12/21/20 Canaccord
Boeing not in position to challenge Aerojet bid, says Canaccord
12/21/20 RBC Capital
Aerojet Rocketdyne price target raised to $56 from $51 at RBC Capital
11/03/20 Morgan Stanley
Morgan Stanley sees attractive buying opportunity in Defense stocks
10/21/20 RBC Capital
Lockheed Martin price target raised to $414 from $405 at RBC Capital
AJRD Aerojet Rocketdyne
$52.10 /

+9.97 (+23.66%)

12/21/20 Truist
Aerojet Rocketdyne downgraded to Hold from Buy at Truist
10/27/20 Truist
Aerojet Rocketdyne price target lowered to $54 from $60 at Truist
RP RealPage
$87.43 /

+19.79 (+29.26%)

11/03/20 DA Davidson
RealPage price target lowered to $65 from $70 at DA Davidson
08/19/20
Fly Intel: Top five analyst initiations
08/19/20 Goldman Sachs
RealPage initiated with a Neutral at Goldman Sachs
07/17/20 RBC Capital
RealPage price target raised to $74 from $66 at RBC Capital
NKE Nike
$144.37 /

+5.33 (+3.83%)

12/21/20 Jefferies
Nike price target raised to $140 from $117 at Jefferies
12/21/20 Baird
Nike near-term estimate upside limited, says Baird
12/21/20 Raymond James
Nike price target raised to $155 from $140 at Raymond James
12/21/20 Wells Fargo
Nike price target raised to $157 from $146 at Wells Fargo
TSLA Tesla
$664.48 /

-1.32 (-0.20%)

12/21/20 Wedbush
Tesla price target raised to $715 from $560 at Wedbush
12/18/20 Wedbush
Tesla in position to be on offensive heading into 2021, says Wedbush
12/17/20 Barclays
Tesla price target raised to $230 from $125 at Barclays
12/17/20 Barclays
Lear upgraded to Overweight from Equal Weight at Barclays
WBAI 500.com
$4.17 /

+1.515 (+57.06%)

NK NantKwest
$16.78 /

+6.54 (+63.87%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
QURE uniQure
$37.97 /

-7.93 (-17.28%)

12/21/20 Stifel
AMT-061 clinical hold 'obviously negative,' implications less clear, says Stifel
12/21/20 H.C. Wainwright
uniQure price target raised to $85 from $80 at H.C. Wainwright
12/09/20 Jefferies
uniQure price target raised to $62 from $55 at Jefferies
12/09/20 Mizuho
uniQure price target raised to $52 from $46 at Mizuho
FGEN FibroGen
$38.75 /

-5.24 (-11.91%)

12/21/20 Mizuho
FibroGen should be bought on PDUFA extension weakness, says Mizuho
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
TSLA Tesla
$664.48 /

-1.32 (-0.20%)

RP RealPage
$87.43 /

+19.79 (+29.26%)

QURE uniQure
$37.97 /

-7.93 (-17.28%)

NKE Nike
$144.37 /

+5.33 (+3.83%)

LMT Lockheed Martin
$351.88 /

-4.35 (-1.22%)

FGEN FibroGen
$38.75 /

-5.24 (-11.91%)

AJRD Aerojet Rocketdyne
$52.10 /

+9.97 (+23.66%)

  • 25
    Jun
  • 20
    May
  • 14
    Feb
TSLA Tesla
$664.48 /

-1.32 (-0.20%)

QURE uniQure
$37.97 /

-7.93 (-17.28%)

NKE Nike
$144.37 /

+5.33 (+3.83%)

LMT Lockheed Martin
$351.88 /

-4.35 (-1.22%)

TSLA Tesla
$664.48 /

-1.32 (-0.20%)

RP RealPage
$87.43 /

+19.79 (+29.26%)

QURE uniQure
$37.97 /

-7.93 (-17.28%)

NKE Nike
$144.37 /

+5.33 (+3.83%)

NK NantKwest
$16.78 /

+6.54 (+63.87%)

LMT Lockheed Martin
$351.88 /

-4.35 (-1.22%)

FGEN FibroGen
$38.75 /

-5.24 (-11.91%)

AJRD Aerojet Rocketdyne
$52.10 /

+9.97 (+23.66%)

TSLA Tesla
$664.48 /

-1.32 (-0.20%)

NKE Nike
$144.37 /

+5.33 (+3.83%)

NK NantKwest
$16.78 /

+6.54 (+63.87%)

FGEN FibroGen
$38.75 /

-5.24 (-11.91%)

Recommendations
AMT-061 clinical hold 'obviously negative,' implications less clear, says Stifel » 10:26
12/21/20
12/21
10:26
12/21/20
10:26
QURE

uniQure

$37.99 /

-7.91 (-17.23%)

Stifel analyst Paul…

Stifel analyst Paul Matteis acknowledges that uniQure's announcement of AMT-061 clinical hold is "obviously negative," but notes that at this stage "it's simply less clear what the actual implications will be." The analyst believes "a lot is at stake," including the regulatory prospects of AMT-061, AMT-061 commercial potential, and cash flows via the CSL deal. While the stock deserves to be down some, post-deal close, uniQure should have almost $700M in cash to fund Huntington's and the rest of its pipeline, he contends. Matteis has a Buy rating on the shares.

ShowHide Related Items >><<
QURE uniQure
$37.99 /

-7.91 (-17.23%)

QURE uniQure
$37.99 /

-7.91 (-17.23%)

12/21/20 H.C. Wainwright
uniQure price target raised to $85 from $80 at H.C. Wainwright
12/09/20 Jefferies
uniQure price target raised to $62 from $55 at Jefferies
12/09/20 Mizuho
uniQure price target raised to $52 from $46 at Mizuho
11/24/20 H.C. Wainwright
uniQure assumed with a Buy at H.C. Wainwright
QURE uniQure
$37.99 /

-7.91 (-17.23%)

QURE uniQure
$37.99 /

-7.91 (-17.23%)

QURE uniQure
$37.99 /

-7.91 (-17.23%)

Hot Stocks
uniQure says hemophilia B gene therapy program placed on clinical hold » 07:07
12/21/20
12/21
07:07
12/21/20
07:07
QURE

uniQure

$45.98 /

-2.08 (-4.33%)

uniQure announced that…

uniQure announced that its hemophilia B gene therapy program, including the pivotal, Phase III HOPE-B study, has been placed on clinical hold by the U.S. Food and Drug Administration. Patient dosing is complete in each of uniQure's three hemophilia B gene therapy studies, and there is no plan to enroll or treat additional patients. The clinical hold was initiated following the submission of a safety report in mid-December relating to a possibly related serious adverse event associated with a preliminary diagnosis of hepatocellular carcinoma, a form of liver cancer, in one patient in the HOPE-B trial that was treated with etranacogene dezaparvovec in October 2019. The patient has multiple risk factors associated with HCC, including a twenty-five-year history of hepatitis C, hepatitis B virus, evidence of non-alcoholic fatty liver disease and advanced age. Chronic infections with hepatitis B and C have been associated with approximately 80% of HCC cases.1 The liver lesion was detected during a routine abdominal ultrasound conducted as part of the required study assessments in patients at one-year post dosing. A full surgical resection of the lesion is scheduled this week that will allow for confirmation of the diagnosis. No other cases of HCC have been reported in uniQure clinical trials conducted in more than 100 patients in hemophilia B and other indications, with some patients dosed more than 10 years ago. "Patient safety will always be our top priority, and we are working closely with the FDA and our advisors to conduct a thorough investigation into the cause of this event which we expect to be completed in early 2021," said Ricardo Dolmetsch, Ph.D., president of research and development at uniQure. "We will investigate whether there is a relationship to treatment. At this time, we do not have adequate data to determine a possible causal relationship, especially in the context of the other known risk factors."

ShowHide Related Items >><<
QURE uniQure
$45.98 /

-2.08 (-4.33%)

QURE uniQure
$45.98 /

-2.08 (-4.33%)

12/21/20 H.C. Wainwright
uniQure price target raised to $85 from $80 at H.C. Wainwright
12/09/20 Jefferies
uniQure price target raised to $62 from $55 at Jefferies
12/09/20 Mizuho
uniQure price target raised to $52 from $46 at Mizuho
11/24/20 H.C. Wainwright
uniQure assumed with a Buy at H.C. Wainwright
QURE uniQure
$45.98 /

-2.08 (-4.33%)

QURE uniQure
$45.98 /

-2.08 (-4.33%)

QURE uniQure
$45.98 /

-2.08 (-4.33%)

Recommendations
uniQure price target raised to $85 from $80 at H.C. Wainwright » 06:13
12/21/20
12/21
06:13
12/21/20
06:13
QURE

uniQure

$45.98 /

-2.08 (-4.33%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on uniQure to $85 from $80 and reiterates a Buy rating on the shares. EtranaDez appears well positioned to lead in hemophilia B, Trucchio tells investors in a research note.

ShowHide Related Items >><<
QURE uniQure
$45.98 /

-2.08 (-4.33%)

QURE uniQure
$45.98 /

-2.08 (-4.33%)

12/09/20 Jefferies
uniQure price target raised to $62 from $55 at Jefferies
12/09/20 Mizuho
uniQure price target raised to $52 from $46 at Mizuho
11/24/20 H.C. Wainwright
uniQure assumed with a Buy at H.C. Wainwright
11/20/20 Baird
Baird ups uniQure target to $70, names 'Fresh Pick' into presentation
QURE uniQure
$45.98 /

-2.08 (-4.33%)

QURE uniQure
$45.98 /

-2.08 (-4.33%)

QURE uniQure
$45.98 /

-2.08 (-4.33%)

Recommendations
uniQure price target raised to $62 from $55 at Jefferies » 08:14
12/09/20
12/09
08:14
12/09/20
08:14
QURE

uniQure

$47.37 /

+0.2 (+0.42%)

Jefferies analyst Suji…

Jefferies analyst Suji Jeong raised the firm's price target on uniQure to $62 from $55 and keeps a Buy rating on the shares after the company shared "positive" data at the ASH meeting for EtranaDez in hemophilia B, which the analyst said support durable efficacy and safety. The Phase 3 topline data supports estimated U.S. EU launches of EtranaDez in 2022/2023, said Jeong.

ShowHide Related Items >><<
QURE uniQure
$47.37 /

+0.2 (+0.42%)

QURE uniQure
$47.37 /

+0.2 (+0.42%)

12/09/20 Mizuho
uniQure price target raised to $52 from $46 at Mizuho
11/24/20 H.C. Wainwright
uniQure assumed with a Buy at H.C. Wainwright
11/20/20 Baird
Baird ups uniQure target to $70, names 'Fresh Pick' into presentation
11/19/20 Cowen
uniQure data for EtranaDez 'very solid,' says Cowen
QURE uniQure
$47.37 /

+0.2 (+0.42%)

QURE uniQure
$47.37 /

+0.2 (+0.42%)

QURE uniQure
$47.37 /

+0.2 (+0.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.